Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2022 Mar 22

PMID 35314480

Authors

Bart J Kramers

Iris W Koorevaar

Maatje D A van Gastel

Harry van Goor

Kenneth R Hallows

Hiddo L Heerspink

Hui Li

Wouter N Leonhard

Dorien J M Peters

Jiedong Qiu

Daan J Touw

Ron T Gansevoort

Esther Meijer

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: The vasopressin V2 receptor antagonist tolvaptan is the only drug that has been proven to be nephroprotective in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan also causes polyuria, limiting tolerability. We hypothesized that cotreatment with hydrochlorothiazide or metformin may ameliorate this side effect.

Design, Setting, Participants, & Measurements: We performed a clinical study and an animal study. In a randomized, controlled, double-blind, crossover trial, we included 13 tolvaptan-treated patients with ADPKD. Patients were treated for three 2-week periods with hydrochlorothiazide, metformin, or placebo in random order. Primary outcome was change in 24-hour urine volume. We also measured GFR and a range of metabolic and kidney injury markers.

Results: Patients (age 45±8 years, 54% women, measured GFR of 55±11 ml/min per 1.73 m) had a baseline urine volume on tolvaptan of 6.9±1.4 L/24 h. Urine volume decreased to 5.1 L/24 h (<0.001) with hydrochlorothiazide and to 5.4 L/24 h (<0.001) on metformin. During hydrochlorothiazide treatment, plasma copeptin (surrogate for vasopressin) decreased, quality of life improved, and several markers of kidney damage and glucose metabolism improved. Metformin did not induce changes in these markers or in quality of life. Given these results, the effect of adding hydrochlorothiazide to tolvaptan was investigated on long-term kidney outcome in an animal experiment. Water intake in tolvaptan-hydrochlorothiazide cotreated mice was 35% lower than in mice treated with tolvaptan only. Combination treatment was superior to "no treatment" on markers of disease progression (kidney weight, =0.003 and cystic index, =0.04) and superior or equal to tolvaptan alone.

Conclusions: Both metformin and hydrochlorothiazide reduced tolvaptan-caused polyuria in a short-term study. Hydrochlorothiazide also reduced polyuria in a long-term animal model without negatively affecting nephroprotection.

Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_03_21_CJN11260821.mp3.

Citing Articles

Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update.

Gittus M, Haley H, Harris T, Borrows S, Padmanabhan N, Gale D BMC Nephrol. 2025; 26(1):79.

PMID: 39953521 PMC: 11827152. DOI: 10.1186/s12882-025-03960-4.

Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

St Pierre K, Cashmore B, Bolignano D, Zoccali C, Ruospo M, Craig J Cochrane Database Syst Rev. 2024; 10:CD010294.

PMID: 39356039 PMC: 11445802. DOI: 10.1002/14651858.CD010294.pub3.

Long-term effect of increasing water intake on repeated self-assessed health-related quality of life (HRQoL) in autosomal dominant polycystic kidney disease.

Rangan G, Allman-Farinelli M, Boudville N, Fernando M, Haloob I, Harris D Clin Kidney J. 2024; 17(7):sfae159.

PMID: 39165901 PMC: 11333960. DOI: 10.1093/ckj/sfae159.

Cross-Species Insights into Autosomal Dominant Polycystic Kidney Disease: Provide an Alternative View on Research Advancement.

Luo J, Zhang Y, Jayaprakash S, Zhuang L, He J Int J Mol Sci. 2024; 25(11).

PMID: 38891834 PMC: 11171680. DOI: 10.3390/ijms25115646.

The Effect of Thiazide Diuretics on Urinary Prostaglandin E2 Excretion and Serum Sodium in the General Population.

Geurts F, Rudolphi C, Pelouto A, van der Burgh A, Salih M, Imenez Silva P J Clin Endocrinol Metab. 2024; 109(10):2444-2451.

PMID: 38776231 PMC: 11403316. DOI: 10.1210/clinem/dgae352.

References

Lantinga-van Leeuwen I, Leonhard W, van de Wal A, Breuning M, Verbeek S, de Heer E . Transgenic mice expressing tamoxifen-inducible Cre for somatic gene modification in renal epithelial cells. Genesis. 2006; 44(5):225-32. DOI: 10.1002/dvg.20207. View

Blonde L, Dailey G, Jabbour S, Reasner C, Mills D . Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004; 20(4):565-72. DOI: 10.1185/030079904125003278. View

Leemasawatdigul K, Gappa-Fahlenkamp H . Effect of storage conditions on the stability of recombinant human MCP-1/CCL2. Biologicals. 2010; 39(1):29-32. PMC: 3025303. DOI: 10.1016/j.biologicals.2010.09.003. View

Takiar V, Nishio S, Seo-Mayer P, King Jr J, Li H, Zhang L . Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011; 108(6):2462-7. PMC: 3038735. DOI: 10.1073/pnas.1011498108. View

Bankir L, Perucca J, Norsk P, Bouby N, Damgaard M . Relationship between Sodium Intake and Water Intake: The False and the True. Ann Nutr Metab. 2017; 70 Suppl 1:51-61. DOI: 10.1159/000463831. View

Leonhard W, Song X, Kanhai A, Iliuta I, Bozovic A, Steinberg G . Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine. 2019; 47:436-445. PMC: 6796518. DOI: 10.1016/j.ebiom.2019.08.041. View

Brosnahan G, Wang W, Gitomer B, Struemph T, George D, You Z . Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2021; 79(4):518-526. PMC: 8837717. DOI: 10.1053/j.ajkd.2021.06.026. View

Irazabal M, Rangel L, Bergstralh E, Osborn S, Harmon A, Sundsbak J . Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2014; 26(1):160-72. PMC: 4279733. DOI: 10.1681/ASN.2013101138. View

Gaspari F, Perico N, Matalone M, Signorini O, Azzollini N, Mister M . Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol. 1998; 9(2):310-3. DOI: 10.1681/ASN.V92310. View

10.

Crawford J, Kennedy G, HILL L . Clinical results of treatment of diabetes insipidus with drugs of the chlorothiazide series. N Engl J Med. 1960; 262:737-43. DOI: 10.1056/NEJM196004142621501. View

11.

Nauta F, Bakker S, Heerspink H, de Zeeuw D, van Oeveren W, Bilo H . Effect of frozen storage on urinary concentration of kidney damage markers. Am J Kidney Dis. 2011; 59(4):586-9. DOI: 10.1053/j.ajkd.2011.11.025. View

12.

Torres V, Harris P, Pirson Y . Autosomal dominant polycystic kidney disease. Lancet. 2007; 369(9569):1287-1301. DOI: 10.1016/S0140-6736(07)60601-1. View

13.

Koomans H, Boer W, Dorhout Mees E . Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int. 1989; 36(1):2-12. DOI: 10.1038/ki.1989.153. View

14.

Blair H, Keating G . Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs. 2015; 75(15):1797-806. DOI: 10.1007/s40265-015-0475-x. View

15.

Brochner-Mortensen J . A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest. 1972; 30(3):271-4. DOI: 10.3109/00365517209084290. View

16.

Bird N, Michell A, Peters A . Accurate measurement of extracellular fluid volume from the slope/intercept technique after bolus injection of a filtration marker. Physiol Meas. 2009; 30(12):1371-9. DOI: 10.1088/0967-3334/30/12/006. View

17.

Pei Y, Obaji J, Dupuis A, Paterson A, Magistroni R, Dicks E . Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2008; 20(1):205-12. PMC: 2615723. DOI: 10.1681/ASN.2008050507. View

18.

Gansevoort R, Arici M, Benzing T, Birn H, Capasso G, Covic A . Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016; 31(3):337-48. PMC: 4762400. DOI: 10.1093/ndt/gfv456. View

19.

Kim G, Lee J, Oh Y, Chang H, Joo K, Na K . Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel. J Am Soc Nephrol. 2004; 15(11):2836-43. DOI: 10.1097/01.ASN.0000143476.93376.04. View

20.

Seliger S, Abebe K, Hallows K, Miskulin D, Perrone R, Watnick T . A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2018; 47(5):352-360. PMC: 6010317. DOI: 10.1159/000488807. View